Rio999
2022-02-18
淋巴癌 不容易。
主动暂停临床，是诚实公司的表现。
调整配方后，继续实验。
a good try anyway
Legend Biotech slips after FDA clinical hold on blood cancer study for CAR-T therapy
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":638839155,"tweetId":"638839155","gmtCreate":1645167456306,"gmtModify":1645167456563,"author":{"id":3486361727758741,"authorId":3486361727758741,"authorIdStr":"3486361727758741","name":"Rio999","avatar":"https://static.tigerbbs.com/c1e4178e32cb0fcff4b50f4dce9cc6b4","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":17,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>淋巴癌 不容易。</p><p>主动暂停临床，是诚实公司的表现。</p><p><br></p><p>调整配方后，继续实验。</p><p><br></p><p>a good try anyway</p></body></html>","htmlText":"<html><head></head><body><p>淋巴癌 不容易。</p><p>主动暂停临床，是诚实公司的表现。</p><p><br></p><p>调整配方后，继续实验。</p><p><br></p><p>a good try anyway</p></body></html>","text":"淋巴癌 不容易。 主动暂停临床，是诚实公司的表现。 调整配方后，继续实验。 a good try anyway","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/638839155","repostId":2211631922,"repostType":2,"repost":{"id":"2211631922","pubTimestamp":1644933391,"share":"https://www.laohu8.com/m/news/2211631922?lang=&edition=full","pubTime":"2022-02-15 21:56","market":"us","language":"en","title":"Legend Biotech slips after FDA clinical hold on blood cancer study for CAR-T therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2211631922","media":"seekingalpha","summary":"Grandbrothers/iStock Editorial via Getty Images Legend Biotech (NASDAQ:LEGN) is trading ~6% lower ","content":"<html><body><p><figure> <picture> <img height=\"1024px\" src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w750\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg?io=getty-c-w240 240w\" width=\"1536px\"/> </picture> <figcaption><p>Grandbrothers/iStock Editorial via Getty Images</p></figcaption> </figure></p> <ul> <li>Legend Biotech <span>(NASDAQ:LEGN)</span> is trading <span>~6% lower</span> in the pre-market on Tuesday after the company announced that the U.S<span> Food and Drug Administration (FDA) imposed a clinical hold on its Phase 1 trial for LB1901.</span> </li> <li>An autologous chimeric antigen receptor T-cell (CAR-T) therapy, LB1901, is designed to target cancerous CD4+ T-cells in the treatment of adults with relapsed or refractory T-cell lymphoma (TCL).</li> <li>The FDA informed its decision via e-mail on Feb. 11, and the federal agency had indicated that it would send the official clinical hold letter on Mar. 11, according to the company.</li> <li>Before the notification on clinical hold, the company had dosed only <a href=\"https://laohu8.com/S/AONE.U\">one</a> patient in the study. However, after the patient experienced low CD4+ T-cell counts, Legend (LEGN) had decided to pause the trial and notified the FDA.</li> <li>“The patient has not experienced drug-related serious adverse events (SAEs) and is being monitored in accordance with the protocol,” the company added. </li> <li><p>In October, Allogene <span>(NASDAQ:ALLO)</span> was slapped with a clinical hold by the FDA on its AlloCAR T trials. However, early this year, the company announced that the agency removed the clinical hold.</p></li> </ul></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech slips after FDA clinical hold on blood cancer study for CAR-T therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech slips after FDA clinical hold on blood cancer study for CAR-T therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-15 21:56 GMT+8 <a href=https://seekingalpha.com/news/3800074-legend-biotech-slips-after-fda-clinical-hold-on-blood-cancer-study-for-car-t-therapy><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Grandbrothers/iStock Editorial via Getty Images Legend Biotech (NASDAQ:LEGN) is trading ~6% lower in the pre-market on Tuesday after the company announced that the U.S Food and Drug Administration (...</p>\n\n<a href=\"https://seekingalpha.com/news/3800074-legend-biotech-slips-after-fda-clinical-hold-on-blood-cancer-study-for-car-t-therapy\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LEGN":"传奇生物","CAR":"安飞士","BK4022":"陆运","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"source_url":"https://seekingalpha.com/news/3800074-legend-biotech-slips-after-fda-clinical-hold-on-blood-cancer-study-for-car-t-therapy","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2211631922","content_text":"Grandbrothers/iStock Editorial via Getty Images Legend Biotech (NASDAQ:LEGN) is trading ~6% lower in the pre-market on Tuesday after the company announced that the U.S Food and Drug Administration (FDA) imposed a clinical hold on its Phase 1 trial for LB1901. An autologous chimeric antigen receptor T-cell (CAR-T) therapy, LB1901, is designed to target cancerous CD4+ T-cells in the treatment of adults with relapsed or refractory T-cell lymphoma (TCL). The FDA informed its decision via e-mail on Feb. 11, and the federal agency had indicated that it would send the official clinical hold letter on Mar. 11, according to the company. Before the notification on clinical hold, the company had dosed only one patient in the study. However, after the patient experienced low CD4+ T-cell counts, Legend (LEGN) had decided to pause the trial and notified the FDA. “The patient has not experienced drug-related serious adverse events (SAEs) and is being monitored in accordance with the protocol,” the company added. In October, Allogene (NASDAQ:ALLO) was slapped with a clinical hold by the FDA on its AlloCAR T trials. However, early this year, the company announced that the agency removed the clinical hold.","news_type":1},"isVote":1,"tweetType":1,"viewCount":704,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":77,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/638839155"}
精彩评论